Compare REPL & URG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REPL | URG |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 692.8M | 594.4M |
| IPO Year | 2018 | 2006 |
| Metric | REPL | URG |
|---|---|---|
| Price | $7.65 | $1.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $11.13 | $2.46 |
| AVG Volume (30 Days) | 1.4M | ★ 7.8M |
| Earning Date | 05-21-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.25 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $27,207,000.00 |
| Revenue This Year | N/A | $200.42 |
| Revenue Next Year | N/A | $98.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.68 | $0.55 |
| 52 Week High | $13.24 | $2.35 |
| Indicator | REPL | URG |
|---|---|---|
| Relative Strength Index (RSI) | 52.32 | 48.54 |
| Support Level | $6.71 | $1.47 |
| Resistance Level | $8.07 | $1.70 |
| Average True Range (ATR) | 0.49 | 0.11 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 80.07 | 46.99 |
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
Ur-Energy Inc is engaged in uranium mining and recovery operations, with activities including the acquisition, exploration, development, and production of uranium mineral resources located in Wyoming. The company owns and operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming, Lost Creek received an amendment to its license allowing the expansion of mining activities within the existing Lost Creek Project and the adjacent LC East Project.